Trial Profile

Phase II Study of CDK 4/6 Inhibitor, LEE011 (Ribociclib), in Combination With Adjuvant Endocrine Therapy at Varying Duration for ER-positive Breast Cancer (LEADER)

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 26 Aug 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ribociclib (Primary) ; Aromatase inhibitors
Indications Advanced breast cancer; Early breast cancer; HER2 negative breast cancer
Focus Therapeutic Use
Acronyms LEADER

Most Recent Events

08 Aug 2025 Planned primary completion date changed from 1 Oct 2024 to 1 Oct 2025.
08 Aug 2025 Status changed from recruiting to active, no longer recruiting.
06 Dec 2023 According to a Natera media release, data from this study are being presented at the 2023 San Antonio Breast Cancer Symposium (SABCS).

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com